CONDITIONS TREATeD / TYPE 1 DIABETES
Regenerate. Repair. Restore.
Stem Cells Therapy for Type 1 Diabetes Mellitus
WHAT IS STEM CELL THERAPY?
HOW STEM CELL THERAPY WILL HELP?
WHAT SETS US APART?
WHY STEM CELLS TRANSPLANT INSTITUTE?
Type 1 diabetes mellitus is a life-long disease that requires daily insulin injections and can lead to other serious medical complications.
Treatment at the Stem Cells Transplant Institute could help improve the following symptoms of type I diabetes:
- Excessive thirst
- Frequent Urination
- Excessive hunger
- Fatigue
- Blurred Vision
- Unexplained weight loss
- Irritability
- Frequent infections
- Slow healing sores (e.g. gum infections, vaginal infections)
- Dizziness
What is type 1 diabetes?
The incidence of the chronic and devastating disease of type 1 diabetes has been rising at a rapidly. Approximately 10% of diabetes cases are type 1.
Patients with type 1 diabetes do not produce insulin, but the cause is still unknown. Normally, the immune system produces antibodies which protect the body from foreign invaders such as viruses, bacteria, and germs. In patients with type 1 diabetes, the immune system mistakenly attacks and destroys the healthy insulin-producing beta cells in the pancreas; Resulting in little, to no insulin available to transport sugar into cells. Therefore, sugar builds up in the blood stream and causes systemic damage.
Type 1 diabetes symptoms can appear suddenly at any age, but the majority of patients are diagnosed in early childhood or adolescence. Possible symptoms include: excessive urination, thirst, constant hunger, unexplained weight loss, changes in vision, and fatigue.
Serious complications caused by type 1 diabetes2-4:
- Organ damage, including damage to the heart, kidneys, eyes, blood vessels, and nerves
- Heart attack and/or stroke
- Foot ulcers, infection, and limb amputation
- Blindness
- Kidney failure
Why should I consider stem cell therapy?
According to Researchers mesenchymal stem cells have the potential to treat many chronic diseases, including type 1 diabetes. Mesenchymal stem cells have the ability to:
- Differentiate
- Self-renew
- Suppress the immune system
- Reduce inflammation
- Repair tissue
In type 1 diabetes, mesenchymal stem cells can help reduce beta cell destruction and retain beta cell function.
Mesenchymal stem cells have the ability to modulate the immune system to prevent it from attacking beta cells by mistake, as well as repair already damaged beta cells. The patient’s new beta cells will function properly and control blood sugar levels.
According to preliminary results from clinical trials, mesenchymal stem cells’ action on the immune system allowed beta cells to regenerate and improve glycemic control in patients with long-term type 1 diabetes. After treatment, patients noticed continuous improvement over time.
What is the recommended treatment protocol for COPD and inflammatory lung disease at the Stem Cells Transplant Institute?
For optimal results, the Stem Cells Transplant Institute recommends the use of human umbilical cord mesenchymal stem cells (hUC-MSCs) for the treatment of type 1 diabetes. Treatment includes:
- Mesenchymal stem cells derived from human umbilical cord blood
- Antioxidant therapy with vitamin C and glutathione
- Ozone therapy
- Platelet-rich plasma therapy (PRP)
What are the advantages of human umbilical cord mesenchymal stem cells?
- Abundant supply containing up to 10 times more stem cells than bone marrow or adipose derived stem cells
- hUC-MSC have immunosuppressors and immunomodulatory properties that allow their use in any individual without rejection- Human Leukocyte Antigen (HLA) matching is not necessary
- Greater proliferation ability than adult autologous stem cells
- They regenerate at a very rapid rate
- They are young and very adaptive
- They have not been impacted by the aging process
- They have not been affected by environmental toxins
Umbilical cord stem cells can be administered multiple times over the course of days - Eliminates the need to collect stem cells from the patient’s fat or hip bone reducing pain and recovery time
What are the challenges?
- Using stem cells to control the patient’s immune system is challenging. In some trials when beta cells were created or transplanted into a patient, their immune system would continue to target and destroy the new cells.
- Scientists are researching ways to better protect the new beta cells from future destruction
UMBILICAL CORD DONATIONS
How Are the Stem Cells Collected?
Our clinic focuses on obtaining healthy stem cells exclusively from umbilical cord blood donors. We collect the placenta once the baby is born, with the parent’s informed consent. Additionally, we follow strict ethical guidelines and collect stem cells from reliable and reputable sources.
INTRAVENUS ADMINISTRATION
How Are the Stem Cells Administered?
Our nursing staff administers the stem cells through an intravenous and intra-pulmonary route. For the most effective outcomes, intravenous administration is preferred.
Please fill this form
Scientific References:
- Fu et al. Stem cell transplantation therapy in Parkinson’s disease. SpringerPlus (2015) 4:597
- Joyce et al. Mesenchymal stem cell for the treatment of neurodegenerative disease. Regen Med. 2010, November, 5(6)933-946. Doi:10.2217/rme.10.72
- Helena Vilaça-Faria, António J. Salgado and Fábio G.
- Teixeira Mesenchymal Stem Cells-derived Exosomes: A New Possible Therapeutic Strategy for Parkinson’s disease. Cells2019, 8(2), 118; doi:3390/cells8020118
Teixeira, F.G.; Carvalho, M.M.; Neves-Carvalho, A.; Panchalingam, K.M.; Behie, L.A.; Pinto, L.; Sousa, N.; Salgado, A.J. Secretome of mesenchymal progenitors from the umbilical cord acts as modulator of neural/glial proliferation and differentiation. Stem Cell Rev.2015, 11, 288–297. [Google Scholar] [CrossRef] [PubMed] - Gao, F.; Chiu, S.M.; Motan, D.A.; Zhang, Z.; Chen, L.; Ji, H.L.; Tse, H.F.; Fu, Q.L.; Lian, Q. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis.2016, 7, e2062. [Google Scholar] [CrossRef] [PubMed]
- Joyce, N.; Annett, G.; Wirthlin, L.; Olson, S.; Bauer, G.; Nolta, J.A. Mesenchymal stem cells for the treatment of neurodegenerative disease. Med.2010, 5, 933–946. [Google Scholar] [CrossRef] [PubMed]
- Fraga, J.S.; Silva, N.A.; Lourenco, A.S.; Goncalves, V.; Neves, N.M.; Reis, R.L.; Rodrigues, A.J.; Manadas, B.; Sousa, N.; Salgado, A.J. Unveiling the effects of the secretome of mesenchymal progenitors from the umbilical cord in different neuronal cell populations. Biochimie2013, 95, 2297–2303. [Google Scholar] [CrossRef] [PubMed]
- Ribeiro, C.A.; Fraga, J.S.; Graos, M.; Neves, N.M.; Reis, R.L.; Gimble, J.M.; Sousa, N.; Salgado, A.J. The secretome of stem cells isolated from the adipose tissue and Wharton jelly acts differently on central nervous system derived cell populations. Stem Cell Res. Ther.2012, 3, 18. [Google Scholar] [CrossRef]
- Ribeiro, C.A.; Salgado, A.J.; Fraga, J.S.; Silva, N.A.; Reis, R.L.; Sousa, N. The secretome of bone marrow mesenchymal stem cells-conditioned media varies with time and drives a distinct effect on mature neurons and glial cells (primary cultures). Tissue Eng. Regen. Med.2011, 5, 668–672. [Google Scholar] [CrossRef]
- Salgado, A.J.; Fraga, J.S.; Mesquita, A.R.; Neves, N.M.; Reis, R.L.; Sousa, N. Role of human umbilical cord mesenchymal progenitors conditioned media in neuronal/glial cell densities, viability, and proliferation. Stem Cells Dev.2010, 19, 1067–1074. [Google Scholar] [CrossRef]
- Martins, L.F.; Costa, R.O.; Pedro, J.R.; Aguiar, P.; Serra, S.C.; Teixeira, F.G.; Sousa, N.; Salgado, A.J.; Almeida, R.D. Mesenchymal stem cells secretome-induced axonal outgrowth is mediated by BDNF. Rep.2017, 7, 4153. [Google Scholar] [CrossRef]
- Serra, S.C.; Costa, J.C.; Assuncao-Silva, R.C.; Teixeira, F.G.; Silva, N.A.; Anjo, S.I.; Manadas, B.; Gimble, J.M.; Behie, L.A.; Salgado, A.J. Influence of passage number on the impact of the secretome of adipose tissue stem cells on neural survival, neurodifferentiation and axonal growth. Biochimie2018, 155, 119–128. [Google Scholar] [CrossRef]
- Assuncao-Silva, R.C.; Mendes-Pinheiro, B.; Patricio, P.; Behie, L.A.; Teixeira, F.G.; Pinto, L.; Salgado, A.J. Exploiting the impact of the secretome of MSCs isolated from different tissue sources on neuronal differentiation and axonal growth. Biochimie2018, 155, 83–91. [Google Scholar] [CrossRef] [PubMed]
